Incretins in the Therapy of Diabetic Kidney Disease |
| |
Authors: | Agnieszka Przezak Weronika Bielka Andrzej Pawlik |
| |
Affiliation: | Department of Physiology, Pomeranian Medical University in Szczecin, 70-111 Szczecin, Poland; (A.P.); (W.B.) |
| |
Abstract: | Diabetic kidney disease is a microvascular complication that occurs in patients with diabetes. It is strongly associated with increased risk of kidney replacement therapy and all-cause mortality. Incretins are peptide hormones derived from the gastrointestinal tract, that besides causing enhancement of insulin secretion after oral glucose intake, participate in many other metabolic processes. Antidiabetic drug classes, such as dipeptidyl peptidase 4 inhibitors and glucagon-like peptide receptor agonists, which way of action is based on incretins facility, not only show glucose-lowering properties but also have nephroprotective functions. The aim of this article is to present the latest information about incretin-based therapy and its influence on diabetic kidney disease appearance and progression, point its potential mechanisms of kidney protection and focus on future therapeutic possibilities bound with these two antidiabetic drug classes. |
| |
Keywords: | diabetes diabetic kidney disease incretins therapy |
|
|